Literature DB >> 11127666

Thromboprophylaxis using a low molecular weight heparin delays fracture repair.

J T Street1, M McGrath, K O'Regan, A Wakai, A McGuinness, H P Redmond.   

Abstract

Low molecular weight heparins are significantly superior to unfractionated heparin or warfarin in the prevention of thromboembolic episodes associated with orthopaedic surgery. Therapeutic doses of heparin and warfarin have been shown to delay bone repair in a rabbit model. The current study investigated the effect of prophylactic administration of a low molecular weight heparin, enoxaparin, on the healing of a closed rabbit rib fracture. Fracture healing was assessed using histomorphometric, histologic, and immunohistochemical methods at 3, 7, and 14 days, and biomechanical testing with torsional loading was assessed after 21 days. Bone repair was significantly attenuated at all times in animals receiving subcutaneous enoxaparin compared with that of the control animals. Numerous putative mechanisms for this phenomenon are discussed, and additional studies are proposed to elucidate the effects of this pharmacologically diverse group of compounds on all aspects of bone physiology and repair.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11127666     DOI: 10.1097/00003086-200012000-00032

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  15 in total

1.  Histopathologic effects of a low molecular weight heparin on bone healing in rats: a promising adjuvant in dacryocystorhinostomy.

Authors:  Mehmet Numan Alp; Ozdamar Fuad Oken; Mustafa Fevzi Sargon; Ahmet Ucaner
Journal:  Int J Ophthalmol       Date:  2016-06-18       Impact factor: 1.779

2.  The influence of low molecular weight heparin on the expression of osteogenic growth factors in human fracture healing.

Authors:  Kambiz Sarahrudi; Georg Kaiser; Anita Thomas; Mark Michel; Harald Wolf; Mehdi Mousavi; Seyedhossein Aharinejad
Journal:  Int Orthop       Date:  2011-10-29       Impact factor: 3.075

3.  Vascular endothelial growth factor: an essential component of angiogenesis and fracture healing.

Authors:  Brandon Beamer; Carolyn Hettrich; Joseph Lane
Journal:  HSS J       Date:  2009-09-09

4.  Does low molecular weight heparin impair anastomotic wound healing?

Authors:  Emre Ergul; Yigit Mehmet Ozgun; Gulten Kiyak; Gonca Barit Ozgun; Birol Korukluoglu; Ahmet Kusdemir
Journal:  J Gastrointest Surg       Date:  2008-12-13       Impact factor: 3.452

5.  Absence of beta3 integrin accelerates early skeletal repair.

Authors:  Diane Hu; Chuanyong Lu; Anna Sapozhnikova; Michael Barnett; Carolyn Sparrey; Theodore Miclau; Ralph S Marcucio
Journal:  J Orthop Res       Date:  2010-01       Impact factor: 3.494

6.  Thromboprophylaxis and orthopaedic surgery: options and current guidelines.

Authors:  Gandhi Nathan Solayar; Fintan John Shannon
Journal:  Malays J Med Sci       Date:  2014-05

7.  Exogenous heparin binds and inhibits bone morphogenetic protein 6 biological activity.

Authors:  Jelena Brkljacic; Martina Pauk; Igor Erjavec; Antonio Cipcic; Lovorka Grgurevic; Renata Zadro; Gareth J Inman; Slobodan Vukicevic
Journal:  Int Orthop       Date:  2013-01-10       Impact factor: 3.075

8.  Effects of antithrombotic drugs fondaparinux and tinzaparin on in vitro proliferation and osteogenic and chondrogenic differentiation of bone-derived mesenchymal stem cells.

Authors:  Argiris Papathanasopoulos; Dimitrios Kouroupis; Karen Henshaw; Dennis McGonagle; Elena A Jones; Peter V Giannoudis
Journal:  J Orthop Res       Date:  2011-03-22       Impact factor: 3.494

9.  The Effect of Low Molecular Weight Heparins on Fracture Healing.

Authors:  Stylianos Kapetanakis; Evangelos Nastoulis; Theano Demesticha; Thespis Demetriou
Journal:  Open Orthop J       Date:  2015-06-26

10.  The effects of dabigatran etexilate on fracture healing in rats: An experimental study.

Authors:  Servet Kerimoglu; Atılgan Onay; Yılmaz Guvercin; Atilla Çitlak; Engin Yenilmez; Gökçen Kerimoglu
Journal:  Indian J Orthop       Date:  2015 May-Jun       Impact factor: 1.251

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.